Evidence map›Paper›PMID 30405152›Full record

ArticleScientific reports2018

Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice.

Songhua Quan, Daniel R Principe, Angela E Dean, Seong-Hoon Park, Paul J Grippo, David Gius, Nobuo Horikoshi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. L-arginine-induced pancreatitis aggravated by inhibiting NaThe Journal of veterinary medical science · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. NAD metabolism in aging and cancer.Experimental biology and medicine (Maywood, N.J.) · 2020
    Article
  10. SIRT2 Contributes to the Regulation of Intestinal Cell Proliferation and Differentiation.Cellular and molecular gastroenterology and hepatology · 2020
    Article
  11. The sirtuin family in cancer.Cell cycle (Georgetown, Tex.) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Songhua QuanDepartment of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Daniel R PrincipeDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Angela E DeanDepartment of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Seong-Hoon ParkDepartment of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Paul J GrippoDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
David GiusDepartment of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. david.gius@northwestern.edu.
Nobuo HorikoshiDepartment of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. nobuo.horikoshi@northwestern.edu.ORCID http://orcid.org/0000-0001-8464-8178
Northwestern University · USUniversity of Illinois Chicago · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic InstabilityR01CA152601 · NCI · VANDERBILT UNIVERSITY · PI BONINI, MARCELO G. · 2010 to 2019
$3.5M
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.R01CA253678 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUS, DAVID · 2021 to 2025
$2.1M
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotypeR01CA214025 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUS, DAVID · 2017 to 2021
$2.0M
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancersR01CA168292 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GIUS, DAVID · 2012 to 2016
$1.9M
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary TumorsR01CA152799 · NCI · VANDERBILT UNIVERSITY · PI GIUS, DAVID · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA152601NCI NIH HHS R01 CA152799NCI NIH HHS R01 CA168292NCI NIH HHS R01 CA214025NCI NIH HHS R01 CA253678
6 · The paper itself

Abstract

Mice lacking Sirt2 spontaneously develop tumors in multiple organs, as well as when expressed in combination with oncogenic Kras

Indexed as

MutationAnimalsCeruletideDisease Models, AnimalDisease SusceptibilityFemaleGenetic Predisposition to DiseaseImmunohistochemistryMaleMiceMice, KnockoutPancreatitisProto-Oncogene Proteins p21(ras)RegenerationSirtuin 2CeruletideKRAS protein, humanProto-Oncogene Proteins p21(ras)Sirtuin 2

Identifiers

PMID30405152
PMCPMC6220268
OpenAlexW2898646253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.